These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 10724029

  • 21. Investigation into the selection frequency of resistant mutants and the bacterial kill rate by levofloxacin and ciprofloxacin in non-mucoid Pseudomonas aeruginosa isolates from cystic fibrosis patients.
    Gillespie T, Masterton RG.
    Int J Antimicrob Agents; 2002 May; 19(5):377-82. PubMed ID: 12007845
    [Abstract] [Full Text] [Related]

  • 22. Comparison of the bactericidal activities and post-antibiotic effects of the Des-F(6)-quinolone BMS-284756, levofloxacin, and ciprofloxacin against methicillin-susceptible and methicillin-resistant Staphylococcus aureus.
    Ryan BM, Mazzucco CE, Lawrence LE, Ho H, Warr G, Barrett JF, Frosco M.
    Eur J Clin Microbiol Infect Dis; 2002 Jan; 21(1):27-34. PubMed ID: 11913498
    [Abstract] [Full Text] [Related]

  • 23. Activity of levofloxacin and ciprofloxacin against urinary pathogens.
    Drago L, De Vecchi E, Mombelli B, Nicola L, Valli M, Gismondo MR.
    J Antimicrob Chemother; 2001 Jul; 48(1):37-45. PubMed ID: 11418511
    [Abstract] [Full Text] [Related]

  • 24. In vitro activity of ciprofloxacin, levofloxacin, and trovafloxacin, alone and in combination with beta-lactams, against clinical isolates of Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Burkholderia cepacia.
    Isenberg HD, Alperstein P, France K.
    Diagn Microbiol Infect Dis; 1999 Feb; 33(2):81-6. PubMed ID: 10091030
    [Abstract] [Full Text] [Related]

  • 25. In vitro susceptibility of recent gram-positive isolates to ciprofloxacin, levofloxacin, and trovafloxacin.
    Isenberg HD, Alperstein P, France K.
    Diagn Microbiol Infect Dis; 1998 Oct; 32(2):115-8. PubMed ID: 9823535
    [Abstract] [Full Text] [Related]

  • 26. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates.
    Kowalski RP, Dhaliwal DK, Karenchak LM, Romanowski EG, Mah FS, Ritterband DC, Gordon YJ.
    Am J Ophthalmol; 2003 Sep; 136(3):500-5. PubMed ID: 12967804
    [Abstract] [Full Text] [Related]

  • 27. Ciprofloxacin resistance and tolerance of Pseudomonas aeruginosa ocular isolates.
    Khan M, Ma K, Wan I, Willcox MD.
    Cont Lens Anterior Eye; 2023 Jun; 46(3):101819. PubMed ID: 36732125
    [Abstract] [Full Text] [Related]

  • 28. Italian survey on comparative levofloxacin susceptibility in 334 clinical isolates of Pseudomonas aeruginosa.
    Segatore B, Setacci D, Perilli M, Franceschini N, De Santis A, Marchetti F, Amicosante G.
    Antimicrob Agents Chemother; 1999 Feb; 43(2):428-31. PubMed ID: 9925553
    [Abstract] [Full Text] [Related]

  • 29. Spectrum and activity of three contemporary fluoroquinolones tested against Pseudomonas aeruginosa isolates from urinary tract infections in the SENTRY Antimicrobial Surveillance Program (Europe and the Americas; 2000): more alike than different!
    Jones RN, Beach ML, Pfaller MA.
    Diagn Microbiol Infect Dis; 2001 Nov; 41(3):161-3. PubMed ID: 11750171
    [Abstract] [Full Text] [Related]

  • 30. In vitro activity of levofloxacin against coagulase-positive and -negative staphylococci.
    Cafiso V, Messina C, Santagati M, Campanile F, Bonfiglio G, Stefani S.
    Drugs Exp Clin Res; 2001 Nov; 27(3):107-11. PubMed ID: 11447768
    [Abstract] [Full Text] [Related]

  • 31. Levofloxacin and ciprofloxacin in vitro activities against 4,003 clinical bacterial isolates collected in 24 Italian laboratories.
    Gesu GP, Marchetti F, Piccoli L, Cavallero A.
    Antimicrob Agents Chemother; 2003 Feb; 47(2):816-9. PubMed ID: 12543701
    [Abstract] [Full Text] [Related]

  • 32. Effects of temperature on the bactericidal activities of ciprofloxacin and levofloxacin against Escherichia coli and Pseudomonas aeruginosa.
    Parte AC, Smith JT.
    Microbios; 1994 Feb; 80(322):31-9. PubMed ID: 7854197
    [Abstract] [Full Text] [Related]

  • 33. In-vitro bacteriostatic activity of levofloxacin and three other fluoroquinolones against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae.
    Frémaux A, Sissia G, Geslin P.
    J Antimicrob Chemother; 1999 Jun; 43 Suppl C():9-14. PubMed ID: 10404331
    [Abstract] [Full Text] [Related]

  • 34. [In vitro short-term bactericidal activity and accumulation of NM394, the active metabolite of prulifloxacin, for Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa: comparison with ciprofloxacin, levofloxacin, and gatifloxacin].
    Shimizu M, Tabata M, Hara T, Araake M, Watabe H, Nishino T.
    Jpn J Antibiot; 2002 Dec; 55(6):791-9. PubMed ID: 12621733
    [Abstract] [Full Text] [Related]

  • 35. Prevalence of resistance to three fluoroquinolones: assessment of levofloxacin disk test error rates and surrogate predictors of levofloxacin susceptibility. AST Surveillance Group.
    Fuchs PC, Barry AL, Brown SD.
    Antimicrob Agents Chemother; 1996 Jul; 40(7):1633-9. PubMed ID: 8807053
    [Abstract] [Full Text] [Related]

  • 36. In vitro activity of four fluoroquinolones against clinical isolates of Pseudomonas aeruginosa determined by the E test.
    Swiatlo E, Moore E, Watt J, McDaniel LS.
    Int J Antimicrob Agents; 2000 Jun; 15(1):73-6. PubMed ID: 10856680
    [Abstract] [Full Text] [Related]

  • 37. Bacteriostatic and bactericidal activities of eight fluoroquinolones against MexAB-OprM-overproducing clinical strains of Pseudomonas aeruginosa.
    Dupont P, Hocquet D, Jeannot K, Chavanet P, Plésiat P.
    J Antimicrob Chemother; 2005 Apr; 55(4):518-22. PubMed ID: 15722391
    [Abstract] [Full Text] [Related]

  • 38. Susceptibilities of bacterial isolates from patients with cancer to levofloxacin and other quinolones.
    Dholakia N, Rolston KV, Ho DH, LeBlanc B, Bodey GP.
    Antimicrob Agents Chemother; 1994 Apr; 38(4):848-52. PubMed ID: 8031057
    [Abstract] [Full Text] [Related]

  • 39. Levofloxacin-imipenem combination prevents the emergence of resistance among clinical isolates of Pseudomonas aeruginosa.
    Lister PD, Wolter DJ.
    Clin Infect Dis; 2005 Feb 15; 40 Suppl 2():S105-14. PubMed ID: 15712098
    [Abstract] [Full Text] [Related]

  • 40. Cefepime, piperacillin/tazobactam, gentamicin, ciprofloxacin, and levofloxacin alone and in combination against Pseudomonas aeruginosa.
    Burgess DS, Nathisuwan S.
    Diagn Microbiol Infect Dis; 2002 Sep 15; 44(1):35-41. PubMed ID: 12376029
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.